Transgenic Zebrafish for Modeling Hepatocellular Carcinoma

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2021 Nov 12

PMID 34766114

Citations 7

Authors

Joji Nakayama

Zhiyuan Gong

Affiliations

Soon will be listed here.

Abstract

Liver cancer is the third leading cause of cancer-related deaths throughout the world, and more than 0.6 million people die from liver cancer annually. Therefore, novel therapeutic strategies to eliminate malignant cells from liver cancer patients are urgently needed. Recent advances in high-throughput genomic technologies have identified de novo candidates for oncogenes and pharmacological targets. However, testing and understanding the mechanism of oncogenic transformation as well as probing the kinetics and therapeutic responses of spontaneous tumors in an intact microenvironment require in vivo examination using genetically modified animal models. The zebrafish () has attracted increasing attention as a new model for studying cancer biology since the organs in the model are strikingly similar to human organs and the model can be genetically modified in a short time and at a low cost. This review summarizes the current knowledge of epidemiological data and genetic alterations in hepatocellular carcinoma (HCC), zebrafish models of HCC, and potential therapeutic strategies for targeting HCC based on knowledge from the models.

Citing Articles

The DUBA-SLC7A11-c-Myc axis is critical for stemness and ferroptosis.

Wang Z, Ouyang L, Liu N, Li T, Yan B, Mao C Oncogene. 2023; 42(36):2688-2700.

PMID: 37537342 DOI: 10.1038/s41388-023-02744-0.

The Role of H2-Calponin Antigen in Cancer Metastasis: Presence of Autoantibodies in Liver Cancer Patients.

Bin X, Luo Y, Sun Z, Lin C, Huang P, Tu Z Int J Mol Sci. 2023; 24(12).

PMID: 37373013 PMC: 10298237. DOI: 10.3390/ijms24129864.

In vivo Drug Screening to Identify Anti-metastatic Drugs in Transgenic Zebrafish.

Nakayama J, Makinoshima H, Gong Z Bio Protoc. 2023; 13(10):e4673.

PMID: 37251091 PMC: 10213071. DOI: 10.21769/BioProtoc.4673.

Gastrulation Screening to Identify Anti-metastasis Drugs in Zebrafish Embryos.

Nakayama J, Makinoshima H, Gong Z Bio Protoc. 2022; 12(19).

PMID: 36313195 PMC: 9548519. DOI: 10.21769/BioProtoc.4525.

Transgenic zebrafish for modeling hepatocellular carcinoma.

Nakayama J, Gong Z MedComm (2020). 2021; 1(2):140-156.

PMID: 34766114 PMC: 8491243. DOI: 10.1002/mco2.29.

References

Hussain S, Schwank J, Staib F, Wang X, Harris C . TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007; 26(15):2166-76. DOI: 10.1038/sj.onc.1210279. View

Rekha R, Amali A, Her G, Yeh Y, Gong H, Hu S . Thioacetamide accelerates steatohepatitis, cirrhosis and HCC by expressing HCV core protein in transgenic zebrafish Danio rerio. Toxicology. 2007; 243(1-2):11-22. DOI: 10.1016/j.tox.2007.09.007. View

Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T . Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005; 24(42):6406-17. DOI: 10.1038/sj.onc.1208788. View

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y . Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology. 1994; 20(5):1231-6. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Matsumoto M, Hsieh T, Zhu N, VanArsdale T, Hwang S, Jeng K . Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol. 1997; 71(2):1301-9. PMC: 191185. DOI: 10.1128/JVI.71.2.1301-1309.1997. View

Liu W, Chen J, Hsu C, Li Y, Chen Y, Lin C . A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology. 2012; 56(6):2268-76. DOI: 10.1002/hep.25914. View

Bae J, Rho J, Lee T, Yun S, Kim H, Choi J . Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep. 2007; 18(4):1007-13. View

10.

Lu J, Hsia Y, Yang W, Lin Y, Li C, Tsai T . Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis. 2011; 33(1):209-19. DOI: 10.1093/carcin/bgr224. View

11.

Mancarella S, Krol S, Crovace A, Leporatti S, Dituri F, Frusciante M . Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression. Cancers (Basel). 2019; 11(10). PMC: 6826694. DOI: 10.3390/cancers11101510. View

12.

Wang F, Yang Y, Shi C, Zhang P, Moyer M, Zhang H . UHRF1 promotes cell growth and metastasis through repression of p16(ink⁴a) in colorectal cancer. Ann Surg Oncol. 2012; 19(8):2753-62. DOI: 10.1245/s10434-011-2194-1. View

13.

Evason K, Francisco M, Juric V, Balakrishnan S, Lopez Pazmino M, Gordan J . Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish. PLoS Genet. 2015; 11(7):e1005305. PMC: 4489858. DOI: 10.1371/journal.pgen.1005305. View

14.

Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, Balabaud C . Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2006; 26(5):774-80. DOI: 10.1038/sj.onc.1209824. View

15.

Gomez A, Wellbrock C, Gutbrod H, Dimitrijevic N, Schartl M . Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. J Biol Chem. 2000; 276(5):3333-40. DOI: 10.1074/jbc.M006574200. View

16.

Wang Z, Zhou J, Fan J, Qiu S, Yu Y, Huang X . Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2008; 14(16):5124-30. DOI: 10.1158/1078-0432.CCR-07-4774. View

17.

Gomaa A, Khan S, Toledano M, Waked I, Taylor-Robinson S . Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008; 14(27):4300-8. PMC: 2731180. DOI: 10.3748/wjg.14.4300. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Letrado P, de Miguel I, Lamberto I, Diez-Martinez R, Oyarzabal J . Zebrafish: Speeding Up the Cancer Drug Discovery Process. Cancer Res. 2018; 78(21):6048-6058. DOI: 10.1158/0008-5472.CAN-18-1029. View

20.

Ming L, Thorgeirsson S, Gail M, Lu P, Harris C, Wang N . Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology. 2002; 36(5):1214-20. DOI: 10.1053/jhep.2002.36366. View